Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WALK: Ad2/HIF-1α/VP16 in Intermittent Claudication
NCT00117650Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2005
- Primary completion
- Sep 2008
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 3
01
Overview
A Phase 2 trial of Ad2/HIF-1α/VP16 in intermittent claudication (IC), Peripheral Arterial Disease (PAD), sponsored by Sanofi. Started Feb 2005; status: completed.
02
Drugs
Ad2/HIF-1α/VP16
03
Conditions
intermittent claudication (IC)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT00117650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117650.